March 26 (Reuters) - Gene therapy maker bluebird bio
said on Tuesday it plans to restate its financial
statements for 2022 and for each of the first three quarters of
2022 and 2023 following accounting errors.
The company has also identified "material weakness in its
internal control over financial reporting", it said.